CMPX•globenewswire•
Compass Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Summary
BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced it granted stock options to two new employees under the Company’s 2025 Inducement Plan and as a material inducement to their employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on January 5, 2026 by globenewswire